Alexander R. Shoemaker
AbbVie (United States)(US)
Publications by Year
Research Areas
Synthesis and Characterization of Heterocyclic Compounds, Bioactive Compounds and Antitumor Agents, DNA Repair Mechanisms, Cancer therapeutics and mechanisms, Cell death mechanisms and regulation
Most-Cited Works
- → An inhibitor of Bcl-2 family proteins induces regression of solid tumours(2005)3,369 cited
- → ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor(2008)1,942 cited
- → Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer(2004)364 cited
- → Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL(2007)294 cited
- → Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins(2008)291 cited
- → Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo(2005)244 cited
- → Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor(2011)175 cited
- → The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo(2011)148 cited
- → Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo(2006)130 cited
- → The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo(2010)120 cited